Literature DB >> 4598084

A preliminary trial of doxorubicin in advanced breast cancer and other malignant disease.

M P Cole, I D Todd, P M Wilkinson.   

Abstract

Doxorubicin in a dose of 60 mg/m(2) has been used in the treatment of 23 patients with advanced malignant disease, 18 of whom had carcinoma of the breast. The drug has significant clinical activity on its own, prolonged dosage may be required to obtain a response, and there is a risk of cerebral metastases becoming manifest during treatment which is otherwise successful. Cardiac toxicity appears to be acceptably low with this dose regimen.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4598084      PMCID: PMC2008997          DOI: 10.1038/bjc.1974.47

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  3 in total

1.  Clinical trials with adriamycin.

Authors:  E Middleman; J Luce; E Frei
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

2.  Adriamycin in the treatment of acute leukaemia.

Authors:  J M Whitehouse; D Crowther; C J Bateman; M E Beard; J S Malpas
Journal:  Br Med J       Date:  1972-02-19

3.  Clinical evaluation of adriamycin, a new antitumour antibiotic.

Authors:  G Bonadonna; S Monfardini; M De Lena; F Fossati-Bellani
Journal:  Br Med J       Date:  1969-08-30
  3 in total
  5 in total

1.  A Brief History of Breast Cancer: Part III - Tumour biology lays the foundation for medical oncology.

Authors:  Ritu Lakhtakia; Ikram Burney
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

2.  Chemotherapy of thyroid carcinoma.

Authors:  S Ahuja; H Ernst
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

3.  Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).

Authors:  Neon Brooks; Mario Campone; Silvia Paddock; Scott Shortenhaus; David Grainger; Jacqueline Zummo; Samuel Thomas; Rose Li
Journal:  Drugs Context       Date:  2017-11-15

4.  Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.

Authors:  Miguel J Gil-Gil; Meritxell Bellet; Milana Bergamino; Serafín Morales; Agustí Barnadas; Luís Manso; Cristina Saura; Adela Fernández-Ortega; Elena Garcia-Martinez; Noelia Martinez-Jañez; Mireia Melé; Patricia Villagrasa; Pamela Celiz; X Perez Martin; Eva Ciruelos; Sonia Pernas
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

5.  Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin.

Authors:  Yan Wang; Zhiqiang Cheng; Jing Xu; Meina Lai; Liming Liu; Min Zuo; Lin Dang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.